The company's January-March net profit fell to 744.5 million rupees ($12.76 million) compared with 3.35 billion rupees a year earlier. Analysts on average had expected fourth-quarter profit of 747 million rupees, according to Thomson Reuters data.
Sales fell 30 percent to 10.4 billion rupees in the quarter.
In November, the U.S. Food and Drug Administration (FDA) issued an import alert, effectively a ban, against Wockhardt's Chikalthana plant in western India. The FDA had imposed a ban on the company's Waluj plant in May.
The United States is Wockhardt's largest market.